Biogen boosts investment in neurology with $1 billion Ionis deal

(Reuters) – Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company’s potential blockbuster drug for spinal muscular atrophy.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *